Clinical Research

Harlan M. Krumholz, MD, Yale American College of Cardiology

American College of Cardiology names renowned cardiologist the next editor-in-chief of its flagship journal

The publication's current editor-in-chief is Valentin Fuster, MD, PhD. Harlan M. Krumholz, MD, will begin his five-year term in 2024.

Thumbnail

Statin therapy benefits high-risk patients with no prior history of CVD

Two separate studies examined the controversial topic of prescribing statins to high-risk elderly patients who do not already have high cholesterol or cardiovascular disease.

doctor fruits vegetables vegetarian diet

Plant-based vs. meat-based diets: Going vegan linked to better cardiovascular health in identical twin study

Researchers focused on 22 pairs of identical twins for 8 weeks, asking one twin to follow a healthy vegan diet and the other to follow a healthy omnivorous diet.

Thumbnail

Interruptions during mammogram reading increase inaccuracies, radiologist burnout

Interruptions while reading breast images contribute to emotions associated with physician burnout, according to a new study. 

Cleveland Clinic's cardiology department is consistently ranked one of the top cardiac centers in the country by U.S. News and World Report.

Cleveland Clinic and Canon establish state-of-the-art research center

The collaboration is part of the Cleveland Innovation District, a more than $500 million public-private partnership for advancing medical research.

Thumbnail

Avidity Biosciences inks drug discovery deal worth up to $2.3B with industry heavyweight

Avidity Biosciences, a San Diego-based biopharmaceutical company, is expanding its ongoing collaboration with Bristol Myers Squibb to identify new cardiovascular therapies.

family caregivers

5 things to know about unpaid caregiving (from a radiologist caregiver’s point of view)

After experiencing firsthand the burdens and rewards of caring for a sick loved one, an academic radiologist underwent an awakening of awareness.

Bayer ends blood thinner trial early due to lack of efficacy

The Independent Data Monitoring Committee recommended Bayer stop the trial due to the drug's poor performance compared to apixaban.